ST.

JOSEPH’S COLLEGE OF PHARMACY

Dharmagiri College Campus, Cherthala-688 524, Kerala, India

PRACTICE SCHOOL REPORT

ON

COMPREHENSIVE PREFORMULATION STRATEGIES FOR THE

DEVELOPMENT OF PHARMACEUTICAL DOSAGE FORMS
[Major Domain: Pharmaceutics]

As per the syllabus prescribed by the

Pharmacy Council of India & Kerala University of Health Sciences

in
Seventh Semester B. Pharm

Done by,

George Danni - 210090505

Jyothilakshmi P - 210090511
Mahadevan M - 210090520
Ashwin V X - 210090500

Under the Supervision of

Dr. Praveen Raj R
Professor, Dept. of Pharmaceutics
St. Joseph’s College of Pharmacy, Cherthala-688 524, Kerala, India

2025

1
 St. Joseph’s College of Pharmacy Department of Pharmaceutics
Dharmagiri College Campus, Naipunnya Road, Cherthala-688 524
Kerala, India
Tel: +91 478-2182138, 2810046, 2821546
Email: principal@[Link]

CERTIFICATE BY THE SUPERVISOR

This is to certify that the Practice School Report titled “COMPREHENSIVE PREFORMULATION
STRATEGIES FOR THE DEVELOPMENT OF PHARMACEUTICAL DOSAGE FORMS” is a
bonafide work carried out by George Danni, Jyothilakshmi P, M Mahadevan and Ashwin V X students
of Seventh semester B. Pharm course (Batch 2022) for 150 hours as per the syllabus prescribed by the
Pharmacy Council of India and Kerala University of Health Sciences under the supervision of myself at
the Dept. of Pharmaceutics, St. Joseph’s College of Pharmacy, Cherthala-688 524, Kerala, India.

Cherthala Dr. Praveen Raj R

01/08/2025 Professor,
Dept. of Pharmaceutics

(Seal)

Affiliated to Kerala University of Health Sciences, Kerala, India

Approved by Pharmacy Council of India & All India Council for Technical Education
Website:[Link]
2
 St. Joseph’s College of Pharmacy
Dharmagiri College Campus, Naipunnya Road, Cherthala-688 524
Tel: +91 478-2182138, 2810046, 2821546
Email: principal@[Link]

CERTIFICATE BY THE PRINCIPAL

This is to certify that the Practice School Report titled “COMPREHENSIVE STRATEGIES FOR THE
DEVELOPMENT OF PHARMACEUTICAL DOSAGE FORMS” is a bonafide work carried out by
George Danni, Jyothilakshmi P, M Mahadevan and Ashwin V X students of Seventh semester B. Pharm
course for 150 hours as per the syllabus prescribed by the Pharmacy Council of India and Kerala University
of Health Sciences under the supervision of [Link] Raj R, Professor, Dept. of Pharmaceutics, St.
Joseph’s College of Pharmacy, Cherthala-688 524, Kerala, India

Cherthala [Link]. Daisy PA

01/08/2025 Principal

(Seal)

Approved by Pharmacy Council of India

Affiliated to Kerala University of Health Sciences, Kerala, India
Website: [Link]

3
 DECLARATION

We hereby declare that the Practice School Report entitled “COMPREHENSIVE

STRATEGIES FOR THE DEVELOPMENT OF PHARMACEUTICAL DOSAGE
FORMS” is a bonafide work carried out by us UNDER THE SUPERVISION OF
[Link] Raj R, Professor, Dept. of Pharmaceutics, St. Joseph’s College of Pharmacy,
Dharmagiri College Campus, Cherthala-688 524, Kerala, India.

No. Name [Link] Sign

01 George Danni 210090505

02 Jyothilakshmi.P 210090511

03 M Mahadevan 210090520

04 Ashwin V X 210090500

Cherthala
01/08/2025

4
 ACKNOWLEDGEMENT

We are grateful to God for His steadfast guidance throughout the

conceptualization, development, and completion of this practice school report.
The masterful execution of this project in an exemplary manner was made feasible
exclusively by His gracious blessings.
We hadn’t been travelling in a vaccum. There were a lots of helping hands, or else
this work might not have achieved its goals At the outset, we wish to express our
profound gratitude to our esteemed Director, Dr. Sr. Betty Carla, and our
distinguished Principal, Dr. Sr. Daisy P.A., along with our esteemed St. Joseph's
College of Pharmacy, Cherthala, for their invaluable guidance and unwavering
support throughout the completion of our project. We would also like to take this
opportunity to convey our heartfelt appreciation to our practice school guide, Dr.
Praveen Raj R, Professor in the Department of Pharmaceutics. We hold him in
the highest regard and extend our deepest respect and admiration.
We wholeheartedly express our profound gratitude to our distinguished
colleagues, especially our class coordinator, Dr. Boby Johns G, Professor and
Head of the Department of Pharmaceutics, alongside Dr. Kavitha Vasudevan,
Professor and Head of the Department of Pharmacognosy, whose steadfast
encouragement and inspiration have significantly propelled us forward.
Additionally, we would like to extend our sincere thanks to our librarian, Mr.
Monu Suresh, for his invaluable support and cooperation throughout the execution
of our project.
Finally, we would like to extend our heartfelt gratitude to our parents for their
unwavering love and support throughout all our endeavors, as well as to our
classmates for their generous assistance and invaluable suggestions, which have
proven instrumental at various stages in the completion of our practice school.

5
 Table of Contents
Module-I
No. Title Page No.

1.1 INTRODUCTION 9

1.2 GOALS OF PREFORMULATION STUDIES 9

1.3 OBJECTIVES OF PREFORMULATION STUDIES 10

Module-II
2.1 PHYSICOCHEMICAL STUDIES OF THE DRUG 11

2.2 SOLUBILITY ANALYSIS 11

2.3 MELTING POINT 11

2.4 PARTICLE SIZE 12

2.5 POLYMORPHISM 16

2.6 DETERMINATION OF pKa 17

Module-III
3.1 DRUG-EXCIPIENT INTERACTIONS 19

3.2 TYPES OF DRUG-EXCIPIENT/ EXCIPIENT- 21

EXCIPIENT INTERACTIONS
3.3 ANALYTICAL METHODS FOR DETERMINING 22
DRUG-EXCIPIENT INTERACTIONS
Module-IV
4.1 KINETICS OF STABILITY STUDIES 24

4.2 RATE AND ORDER OF REACTIONS 25

4.3 STABILITY TESTING 28

4.4 ICH GUIDELINES 29

5.1 CONCLUSION 31

5.2 REFERENCE 32

6
Batch Code: 2021-2025
Year: 2025 St. Joseph’s College of Pharmacy, Cherthala
SEVENTH SEMESTR [Link]. PRACTICE SCHOOL
Major Domain: PHARMACEUTICS
Protocol title: COMPREHENSIVE STRATEGIES FOR THE DEVELOPMENT OF
PHARMACEUTICAL DOSAGE FORMS
Module Distribution

Module I Module II Module III Module IV

(25 Hours) (50 Hours) (25 Hours) (50 Hours)

[Link] 3. Studies on 4. Studies on Drug 5. Stability Analysis

Physicochemical excipient interaction of formulations
properties of
drug and
excipients

2. Relevance and
objectives of study

Total Hours allotted: 150 Total Hours/Week: 12 Total Modules: 04

Practice School group:

[Link]. Sign
1. George Danny 210090505 .............................
2. Jyothilakshmi P 210090511 ..............................
3. M Mahadevan 210090520 .............................

Guide: …………………………
[Seal]

7
 ABSTRACT

The development of pharmaceutical dosage forms is a multifaceted process

that requires a strategic integration of scientific, technological, and
regulatory considerations. This paper presents a comprehensive overview of
the key strategies employed throughout the formulation and development
lifecycle of pharmaceutical dosage forms. It outlines the goals and objectives
of preformulation, emphasizing its role in optimizing drug formulation and
identifying potential formulation challenges. Key physicochemical
parameters such as solubility, melting point, particle size, surface area,
crystallinity, polymorphism, molecular dissociation (pKa), partition
coefficient, and dissolution behavior are explored in detail. It also
emphasizes on the types and mechanisms of drug–excipient interactions—
physical, chemical, and biopharmaceutical—along with analytical methods
such as DSC, DTA, FT-IR, TLC, and HPLC for detecting such interactions.
Furthermore, it addresses the principles of stability kinetics, covering
reaction rate theories, degradation pathways, and the factors influencing rate
of reaction etc. The final sections discuss ICH guidelines for stability testing,
climatic zone considerations, and shelf-life estimation, reinforcing the
importance of stability assessments throughout the drug product lifecycle.

8
 PREFORMULATION CONCEPTS,
DRUG - EXCIPIENTS INTERACTION - DIFFERENT
METHODS, KINETICS OF STABILITY, STABILITY TESTING.

1.1 INTRODUCTION

Preformulation studies are defined as the testing of the physical and

chemical properties of a drug substance alone and in combination with
excipients proposed to be used in the formulation.
Preformulation is the stage in drug and dosage form development before
formulation.
➢ Formulation is developing a drug candidate into a drug product.
➢ Preformulation aims to optimize the process of turning a drug
candidate into a drug product.
➢ During preformulation, the physicochemical properties of drug
candidates have to be determined.
➢ The data generated at this stage allow decisions to be made on the
likely ease of formulation of each drug candidate, indicate the most
appropriate dosage form and highlight any potential issues with
processability.
➢ Physicochemical properties can be split into those that are intrinsic
to the molecule and those that are derived from bulk behavior.
➢ Intrinsic properties are inherent to the molecule and so can only be
altered by chemical modification, while derived properties are the
result of intermolecular interactions and so can be affected by
solid-state form, physical shape and environment among other
factors.
➢ Determination of these properties for a new chemical entity is
termed preformulation.
1.2 GOALS OF PREFORMULATION STUDIES
• To manufacture an ideal dosage form with elegant characters.
• Drug excipient compatibility studies
• To establish the necessary physicochemical parameters of drug and
excipients.
9
1.3 OBJECTIVES OF PREFORMATION STUDIES

➢ To formulate a stable and effective dosage form.

➢ To increase drug stability.

➢ To improve the bioavailability of drug.

➢ To reduce drug excipient incompatibility.

10
 2.1 Physicochemical properties of the drug

1. Melting point.
2. Particle Size & Surface Area.
3. Polymorphism.
4. Crystallinity.
5. Flow properties & Bulk density.
6. Drug-Excipient Compatibility.

2.2 Solubility Analysis: -

1) Aqueous solubility – a) Intrinsic Solubility
b) Ionization Constant
2) Solubilization
3) Thermal effect
4) Partition coefficient
5) Common ion effect
6) Dissolution

2.3 Melting point:

➢ Determination of the Melting point of solids confirms the

properties of the formulated compound and conditions to be
maintained in the formulation process.
➢ So, the determination of the Melting point is essential for
preformulation process. When heat is supplied to the formulated
compound above Melting point range, leads to phase changes
sometimes.
➢ This may lead to conversion of active compound to inactive form.
➢ e.g. Meta stable (low Melting point) stable (high Melting point)

11
Determination of melting point
The melting point of a drug can be measured using three techniques: -

[Link] melting: -

Capillary melting gives information about the melting range but it is

difficult to assign an accurate melting point.
[Link] stage microscopy: -
This is the visual observation of melting under a microscope equipped
with a heated and lagged sample stage. The heating rate is controllable
and up to three transitions can be registered. These values are more
accurate.
[Link] scanning calorimetric and thermal analysis: -
Differential thermal analysis (DTA) and (DSC) measures the temperature
difference between the sample and a reference as a function of
temperature or time when heating at a constant rate.

2.4 Particle size:

Particle size is characterized using these terms:
i. Very coarse
ii. Coarse
iii. Moderately coarse
iv. Fine
v. Very fine

Particle size can influence variety of important factors:

• Dissolution rate.
• Suspendability.
• Uniform distribution.
• Penetrability

12
Methods to Determine Particle Size
• Sieving (5μ-150μ)
• Microscopy (0.2μ-100μ)
• Sedimentation rate method (1μ-200μ)
• Light energy diffraction (0.5μ-500μ)
• Laser holography (1.4μ-100μ)
• Cascade impaction
Laser holography: -
A pulsed laser is fired through an aerosolized particle spray &
photographed in three dimensional with holographic camera, allowing the
particles to be individually imaged & sized.

Cascade impaction:
• The principle that a particle driven by an airstream will hit a surface in
its path, provided that its inertia is sufficient to overcome the force that
tends to keep in it in airstream.
Surface area
• Particle size & surface area are inversely related to each other.
• Smaller the drug particle, greater the surface area.
• Specific surface area is defined as the surface area per unit weight (𝑆𝑤)
or unit volume (𝑆𝑣)of the material.
• Methods for determining surface area:
1. Adsorption method.
2. Air permeability method
Powder flow properties
• Powders must have good flow properties in order to fill tablet presses
or capsule filling machines and to ensure blend uniformity when mixed
with excipients.
• Powder flow properties can be affected by change in particle size,
shape & density.
13
The flow properties depend upon following-
• 1. Force of friction.
• 2. Cohesion between one particle to another.
Fine particle possesses poor flow by filling void spaces between larger
particles causing packing & densification of particles.
By using a glidant/ lubricant we can alter the flow
properties. e.g. Talc, [Link]
Methods to assess powder flow:

• Bulk density.
• Tapped density.
• Compressibility index (Carr’s index).
• Angle of repose.

Bulk density

• The bulk density is the ratio of total mass of powder to the

bulk volume of powder.
• It is measured by pouring the weighed powder into a
granulated measuring cylinder and the volume was noted.
• It is expressed in g/ml and is given by
𝑫𝒃=M/𝑽𝒃
Were,
𝐷𝑏= Bulk density
M= Mass of the powder
𝑉𝑏= Bulk volume of the powder

Tapped density

• The tapped density is the ratio of total mass of powder to the tapped
volume of powder.
• The tapped volume is measured by tapping the powder to constant
volume.
14
 • It is expressed in g/ml and is given by
𝐷𝑡=M/𝑉𝑡
Were,
𝐷𝑡= tapped density
M= Mass of the powder
𝑉𝑡= tapped volume of the powder
Carr’s index (compressibility index)

• Another indirect method of measuring powder flow from bulk and

tapped densities was developed by Carr.
• Carr’s Index (%) = (Tapped Density – Bulk Density)

-------------------------------------------------x100

(Tapped Density)
• Carr’s index is also an indication of flow properties of powder
Angle of repose
• Angles of repose have been used as indirect methods of quantifying
powder flowability.
• A greater angle of repose indicates poor flow.
• It can be determined by the following equation:
• tan θ = h/r
• where, θ = angle of
repose. h=height of pile
• r = radius.
Crystallinity

• Crystal habit & internal structure of drug can affect bulk and
physicochemical properties of the molecule.

Crystal habit is a description of the outer appearance of the crystal.

• Internal structure is molecular arrangement within the solid.
• Change with internal structure usually alters crystal habit.
• Ex: Conversion of sodium salt to its free acid form produces both changes
in internal structure & crystal habit.
15
 2.5 Polymorphism:
• Polymorphs are crystalline substances which are chemically the same but
differ in their physical properties due to different molecular arrangements
i.e. different internal lattices. Such differing factors include density,
melting point, solubility etc.
• The phenomena of existing as different polymorphs is termed
polymorphism.
• Polymorphs are of 2 types
1. Enantiotropic.
2. Monotropic.
• The polymorph which can be changed from one form into another by
varying temperature or pressure is called as Enantiotropic polymorph.
• E.g.: Sulphur.
• One polymorph which is unstable at all temp. & pressure is called as
Monotropic polymorph. The change is irreversible.
• E.g.: Glyceryl stearate.
During Preformulation it is important to;
1. Identify the polymorph that is stable at room temperature.
2. Determine whether polymorphic transitions are possible within
the temperature range and during processing.

• Examples:
• Chloramphenicol exists in A, B & C forms, of this B form is more stable
& most preferable.
• Riboflavin has I, II & III forms, the III form shows 20 times more
water solubility than form I.

Intrinsic properties
• Solubility
• Molecular dissociation(pKa)
• Partition coefficient
• Dissolution

16
Solubility:
Aqueous solubility:
• Aqueous solubility is a critical attribute. No drug will reach its
ultimate therapeutic target without first being in solution.
• Early determination of solubility gives a good indicator as to the ease
of formulation of a drug candidate.
• For the final product, assuming oral delivery in a solid form, solubility
of the molecule above 10 mg/mL is preferable.
• If the solubility of the drug candidate is less than 1 mg/mL then
salt formation, if possible, is indicated.
• Where solubility cannot be manipulated through salt formation, then a
novel dosage form will be required.

Intrinsic solubility:
• The solubility of a compound (an acid or base) in a solvent of
the same nature is the compound’s intrinsic solubility.
• The intrinsic solubility should be measured at two temperatures:
• 4⁰ C to ensure physical and chemical stability.
• 37⁰ C for biopharmaceutical evaluation.
• Intrinsic solubility is the equilibrium solubility of the free acid or
base form of an ionizable compound at a pH where it is fully
unionized.

2.6 Molecular dissociation(pKa):

• Determining the pKa of a drug is the next step in preformulation
characterization.
• This is particularly important with drugs intended for peroral
administration as they will experience a range of pH
environments, and it is important to know how their degree of
ionization may change during passage along the gastrointestinal
tract.
• It is generally agreed that unionized form of the drug is most
suitable for absorption in the GI tract.
• The amount of drug that exists in unionized form is a function of
pKa of the drug and pH of the surrounding medium.

17
 • The Henderson-Hasselbalch equations allow calculation of the
extent of ionization of a drug as a function of pH, if the pKa is known.
• When the pH is significantly below the pKa (by at least 2 pH units),
a weakly acidic drug will be completely unionized and when the pH is
significantly above the pKa (by at least 2 pH units) a weakly acidic drug
will be fully ionized (and vice versa for a basic drug).

• the equation may be re-written as:

pKa = pH + log Concentration of unionized drug

————————
Concentration of ionized drug.

Partition Coefficient:

No solute has complete affinity for either a hydrophilic or a lipophilic phase.

In the context of preformulation, it is important to know early in the
development stage how a molecule (or charged ion) will distribute between
aqueous and fatty environments (e.g. between gut contents and lipid
biological bilayers in the surrounding cell walls).
• When a solute is added to a mixture of two (immiscible) solvents
it will usually dissolve in both to some extent and a position of
equilibrium will be established between the concentrations (C) in the
two solvents.
• In other words, the ratio of the concentrations will be constant and
is given by:

logP = log Concentration of drug in oil phase

————————
Concentration of drug in aqueous phase

18
Dissolution
• Dissolution rate of a drug substance, when combined with the
solubility. partition coefficient, and pKa results provide some insight
into the potential In-vivo absorption characteristics. Dissolution rate
may be affected by chemical form, crystal form, particle size, and
surface properties of a drug
• Chemical form: Acid, base, and salt forms have significant
differences in dissolution rate. (For example, the dissolution rate of
sodium sulfathiazole in 0. 1 N HCI is 5,500 times faster than
sulfathiazole.)
• Crystal form: The metastable form has a greater dissolution rate
compared to the stable form, (For example, sulfathiazole II has a higher
dissolution rate than stable sulfathiazole I.)
• Particle size: A reduction in particle size increases the surface
area of the particles and the dissolution rate.

3.1 DRUG – EXCIPIENT INTERACTIONS

EXCIPIENTS: - Excipients play an important role in formulation in a dosage
form.
These are the ingredients which along with API, make up the dosage form.
Excipients act as protective agents, bulking agents, and can also be used to
improve the bioavailability of drug.

• Drug interactions are said to occur when the pharmacological activity

of a drug is altered by the concomitant use of another drug or by
presence of food, drink or environmental chemicals.
• Excipient: An excipient is a non-medical and an inactive substance
that serves as the vehicle or medium for a drug.
• Drug excipient interactions represent an important phase in Drug
development.
• Drug substances are usually combined with excipients which serve
different and specialized purpose.
Although excipients are pharmacologically inert, they can undergo
chemical reactions and physical interactions with drug substance under
favourable environmental conditions.
19
Importance of Drug-excipient interactions:
• It tells about the stability profile of a dosage form.
• It bridges drug discovery and development.
• It is essential in investigational new drug submission (IND).

2) CHEMICAL PROPERTIES
➢ Oxidation
➢ Hydrolysis
➢ Photolysis
➢ Racemization
➢ Polymerization
➢ Isomerization
➢ Decarboxylation
➢ Enzyme decomposition.

IDEAL PROPERTIES OF EXCIPIENTS: -

An ideal excipient should not have any interaction with the drug or other
excipients
It should not exert any pharmacological action as its own
It should be pharmacologically and pharmaceutically inactive

ROLE OF EXCIPIENTS: -

• Provide bulk to the formulation

• Enhance drug stability
• Improve bioavailability
• Facilitating drug delivery
• Ensure patient compliance
• Addressing formulation challenges

20
 3.2 TYPES OF DRUG–EXCIPIENT OR EXCIPIENT-EXCIPIENT
INTERACTIONS
Physical interactions.

Chemical interactions
Biopharmaceutical interactions
Excipient-excipient interactions

1) PHYSICAL INTERACTION
These are very common in dosage form & also difficult to detect.
These involve change in: -
Dosage uniformity, color, odor, dissolution, stability or
sedimentation rate etc.
These interactions can either be beneficial or detrimental to the
product performance.
Examples of some these interactions are as follow: -

2) CHEMICAL INTERACTION
Chemical interactions involve chemical reaction between drugs &
excipients or drug & impurities /residues present in the excipients to form
different molecules.
Chemical interactions are almost detrimental to the product because they
produce degradation products.

3) BIOPHARMACEUTICAL INTERACTIONS
These are the interactions which are observed after administration of
medicines.
Interaction within the body is between medicine & body fluids which
influence the rate of adsorption. All excipients physiological way when
they are administered along with active pharmaceutical ingredients.

21
Various examples of interactions are: -

a) premature breakdown of enteric coat –Enteric coating polymers.

e.g., cellulose acetate phthalate & hydroxyl propyl cellulose acetate
phthalate.
b) Increase in gastrointestinal motility.

4) EXCIPIENT – EXCIPIENT INTERACTIONS

Excipient–excipient interaction through observed very INTERACTIONS

rarely. These are of prime importance in determining the stability of the
dosage form.
Excipient-excipient interactions can be undesirable as well and some
interactions are used in the formulations to get the desired product
attributes.

3.3 Different analytical methods for determining drug-excipient

interaction:
1. FT-IR Spectroscopy
2. Thermal methods of analysis –
• DSC- Differential Scanning Calorimetry.
• DTA- Differential Thermal Analysis
3. Chromatography –TLC-Thin Layer Chromatography,
HPLC-High Pressure Liquid Chromatography.
4. Miscellaneous – Radio labelled Techniques –
Vapour Pressure Osmometry, Fluorescence
Spectroscopy.

Differential scanning calorimetry

• DSC is widely used to investigate and predict any
physicochemical interaction between drug and excipients involving
thermal changes.

22
METHOD:
• The preformulation screening of drug-excipient interaction
requires (1: 1) Drug: excipient ratio, to maximize the likelihood of
observing an interaction.
• Mixture should be examined under 𝑁2 to eliminate oxidative and
pyrolytic effects at the heating rate on the DSC apparatus.
ADVANTAGES:
• - Fast
• - Reliable and very less samples required.
LIMITATIONS:
• If thermal changes are very small, DSC can’t be used.
• DSC cannot detect the incompatibilities which occur after long-
term storage. E.g. MCC / ASPIRIN.
• Not applicable if test material exhibits properties that make
data interpretation difficult.
DIFFRENTIAL THERMAL ANALYSIS:
• Thermal Analysis is useful in the investigation of solid-state
interactions.
• It is also useful in the detection of eutectics.
• Thermograms are generated for pure components and their
physical mixtures with other components.
• In the absence of any interaction, the thermograms of mixtures
show patterns corresponding to those of the individual components.

Thin Layer Chromatography:

• TLC is a chromatographic method of analysis carried out on glass,
plastic or metal plates coated on one side with a thin layer of
adsorbent.
• The thin layer of adsorbent serves as the stationary phase and is
usually made of silica, alumina, polyamide, cellulose or ion exchange
resin.

23
• In TLC, solutions of the test samples (that is, a mixture of the drug
and the excipient) and the controls (individual drug and excipients) are
prepared and spotted on the same baseline at the end of the plate (the
origin).
• The plate is then placed upright in a closed chamber containing
mixtures of organic solvents which serve as the mobile phase.
• The analyte moves up the plate, under the influence of the mobile
phase which moves through the stationary phase by capillary action.
The distance moved by the analyte is dependent on its relative affinity
for the stationary or the mobile phase.
• An excipient is considered to be potentially compatible with the drug
substance if the spots produced have identical Rf value.
• Rf = Distance travelled by solute
---------------------------------------
Distance travelled by solvent

4.1 KINETICS OF STABILITY

• Stability testing is termed as a complex process because of the
involvement of a variety of factors influencing the stability of
pharmaceutical products.
• These factors include stability of the active ingredients
interaction between excipients, manufacturing process
followed, type of dosage form, container/ closure system used
for packaging & light,
heat & moisture conditions encountered during shipment, storage
& handling.
• In addition, degradation, reactions like oxidation, reduction,
hydrolysis, can play vital role in the stability of pharmaceutical
products.
• Also depends on such conditions like concentration of reactants,
pH, radiation, catalyst etc. as well as raw materials used & the
length of time between manufacture & usage of the product.
• The stability of a pharmaceutical product can also be affected
because of microbiological changes like the growth of
microorganisms is non-sterile products & changes in
preservative efficacy.

24
 STABILITY KINETICS:

• DRUG STABILITY
The capacity of a drug or product to remain within established specifications of
identity, quality, purity in a specific period of time.

• Kinetics deals with the study of the rate at which processes occur and
mechanism of chemical reactions.
• It involves the study of rate of change and the way in which this rate is
influenced by the concentration of reactants, products, and other chemical
species that may be present, and by factors such as solvents, pressure, and
temperature.
4.2 Rate and order of reactions:
• RATE - the speed or velocity of a reaction with which a reactant or
reactants undergoes a change.
• The rate may be determined by the slowest or rate determining step.

ORDERS OF REACTIONS
The number of concentrations that determine rate and the way in which the
concentration of the reactant influences the rate.
Zero order reactions:
• The reaction rate is independent of concentration of the reacting
substance; it depends on the zero power of the reactant and therefore
is zero order reaction.
• The equation can be written as:
dc/dt = -KoCo = -Ko
where,

dc/dt = rate
𝐶0= concentration
𝐾0= zero-order rate constant.

25
 Graph of zero order kinetics showing the relationship between rate of reaction &
concentration of the drug.

First order reactions:

• Whose rate is directly proportional to the concentration of the
drugs undergoing reaction i.e. greater the concentration, faster the
reaction.
• First-order process is said to follow linear kinetics.
• The equation can be written as:
dC/dT = -KC
Were,
K = first-order rate constant
C = concentration.

26
 Graph of first-order kinetics showing the relationship between the rate of reaction &
concentration of drug.

FACTORS AFFECTING RATE OF REACTION

• Temperature
• Light
• Solvent
• Phase & surface area
• Catalysis
• Concentration

THE DRUG DECOMPOSITION FOLLOWS THE DEGRADATION

PATHWAYS: -
• HYDROLYSIS
• OXIDATION
• PHOTOLYSIS
• RACEMIZATION

27
 4.3 STABILITY TESTING:
• Stability is quantitatively expressed as shelf life.

o Shelf life is the time during which the medicinal product is

predicted to remain fit for its intended use under specified
conditions of storage.
o It is the time from manufacture or preparation until the
original potency or content of the active ingredient has been
reduced by 10% [t10 or t90] which is the limit of chemical
degradation.
o To maintain the shelf life of drugs the ICH and WHO
guideline for stability testing should be followed.
Stability testing is incorporated at all stages of the drug product lifecycle, and can be
segregated into 6 stages:
• STAGE 1- Early-stage stress and accelerated testing with
drug substances.
• STAGE 2- Stability on pre-formulation batches.
• STAGE 3- Stress testing on scale-up batches.
• STAGE 4- Accelerated and long-term testing for registration purposes.
• STAGE 5- On-going stability testing.
• STAGE 6- Follow-up stabilities.

CLIMATIC ZONES FOR STABILITY TESTING:

• The stability studies of the drug should be done according to the
climatic conditions of a country. According to the ICH guidelines for
stability studies, the climate of the world is divided into five different
zones:
➢ Zone I-Temperate zone
➢ Zone II-Mediterranean/Subtropical zone
➢ Zone III-Hot dry zone
➢ Zone Iva-Hot humid/tropical zone
➢ Zone Ivb-Hot/higher humidity

28
 4.4 ICH GUIDELINES FOR STABILITY STUDIES:
• The International Conference on Harmonization (ICH) of Technical
Requirements for Registration of Pharmaceuticals for Human Use is a
unique project that brings together the regulatory authorities of Europe,
Japan and the United States and experts from the pharmaceutical industry
in the three regions to discuss scientific and technical aspects of product
registration.
• ICH has published guidelines for conducting stability testing. These
guidance’s provide definitions of key terms and principles used in the
stability testing of drug substances and drug products.
• As our major concern is stability testing, the Q1 guidelines of ICH tell
us about stability testing.

Specific guidelines under Q1:

29
 ESTIMATION OF SHELF LIFE: -
• The time period during which a drug product is expected to remain
within the approved shelf life –specification, provided that it is
stored under the conditions.
• The time period during which the drug maintains its 90% potency or
loss not more than 10% potency.
• The shelf life is determined from the data obtained from the long-
term storage studies.
EXPIRATION OF DATA: -
• An expiration data is defined as the time up to which the product
[will remain stable when stored under recommended storage
conditions.
• Thus, an expiration date is the date beyond which it is predicted
that the product may no longer retain fitness for use.
• If the product is not stored by the manufacturer instructions, then
the product may be expected to degrade more rapidly.

30
 CONCLUSION

Preformulation studies form the cornerstone of successful pharmaceutical

development, providing critical insights into the physicochemical
characteristics of drug candidates and their interactions with excipients.
These investigations are essential for designing stable, effective, and
bioavailable dosage forms. Through comprehensive evaluation of solubility,
melting point, particle size, polymorphism, crystallinity, flow properties, and
compatibility profiles, formulators can predict and mitigate potential
challenges in the formulation process.

The understanding of drug-excipient interactions—whether physical,

chemical, or biopharmaceutical—is fundamental to ensuring product
stability and therapeutic efficacy. Employing analytical techniques such as
DSC, DTA, FT-IR, HPLC, and TLC enables early detection of
incompatibilities, ultimately guiding rational excipient selection and
formulation design.

Stability kinetics, encompassing the rate and order of drug degradation

reactions, underpins the prediction of shelf life and ensures long-term
product performance. Adherence to ICH guidelines for stability testing and
consideration of global climatic zones further enhance the reliability of
stability assessments.

In brief the integration of rigorous preformulation strategies with advanced

analytical methodologies not only accelerates the development timeline but
also enhances the safety, quality, and effectiveness of pharmaceutical
products. As drug molecules become increasingly complex, the role of
preformulation in bridging drug discovery and successful commercialization
becomes ever more vital.

31
 REFERNCE

1. Verma G, Mishra MK. Pharmaceutical preformulation studies in

formulation and development of new dosage form: A review. Int. J.
Pharma Res. Rev. 2016;5(10).
2. Gibson M. Pharmaceutical preformulation and formulation. Drugs
Pharm Sci. 2001;199:199.
3. Ahirwar K, Shukla R. Preformulation studies: a versatile tool in
formulation design. InDrug formulation design 2023 Feb 23.
IntechOpen.
4. Honmane SM. General considerations of design and development of
dosage forms: pre-formulation review. Asian Journal of
Pharmaceutics (AJP). 2017 Oct 11;11(03).
5. Bharate SS, Vishwakarma RA. Impact of preformulation on drug
development. Expert opinion on drug delivery. 2013 Sep
1;10(9):1239-57.
6. Hasan MM, Habib SA, Islam MM, Islam MM, Karim SM, Banik K,
Rashid HA. Pharmaceutical preformulation for product development
& analytical techniques use in new dosage form. International
Journal of Pharmacy & Therapeutics. 2017;8(1):16-32.
7. Gaisford S, Saunders M. Essentials of pharmaceutical
preformulation. John Wiley & Sons; 2012 Oct 22.
8. Adeyeye MC, Brittain HG, editors. Preformulation in solid dosage
form development. CRC Press; 2008 Jan 7.
9. Lau E. Preformulation studies. InSeparation science and technology
2001 Jan 1 (Vol. 3, pp. 173-233). Academic Press.
[Link] R, Buschmann H, Holenz J. Innovative Dosage Forms:
Design and Development at Early Stage. John Wiley & Sons; 2019
Dec 4.
11. Shah SM, Jain AS, Kaushik R, Nagarsenker MS, Nerurkar MJ.
Preclinical formulations: insight, strategies, and practical
considerations. Aaps Pharmscitech. 2014 Oct;15(5):1307-23.
12. Chrzanowski F. Preformulation considerations for controlled release
dosage forms: Part I selecting candidates. AAPS PharmSciTech.
2008 Jun;9(2):635-8.
13. Garg S, Kandarapu R, Vermani K, Tambwekar KR, Garg A, Waller
DP, Zaneveld LJ. Development pharmaceutics of microbicide
formulations. Part I: preformulation considerations and challenges.
AIDS Patient Care and STDs. 2003 Jan 1;17(1):17-32.

32